About the Type 2 Inflammation Patient Navigator
Education, information, and tools.
The aim of this patient education platform is to create more awareness about Eosinophilic Driven Diseases (Type 2 inflammation) and to provide a deeper understanding of what eosinophil-driven type II inflammation diseases are, what the potential treatment options are and which patient organizations provide support for these diseases.
The science of type II inflammation is evolving in areas like COPD and bullous pemphigoid; therefore, not all conditions are fully understood or explained in this tool.
What the Type 2 Inflammatory or Eosinophilic-Driven diseases are?
Eosinophil-Driven Diseases (EDDs) are Type 2 Inflammatory Diseases, that can take several forms. Elevated eosinophils play a crucial role in EDDs. Eosinophilic immune dysfunction is responsible for the recruitment and activation of eosinophils.
It is a systemic allergic response due to an overreactive immune response, causing asthmatic problems and other diseases. The immune system, lungs, gut/stomach, and skin can be affected in different ways. More information: http://gaapp.org/eosinophil-driven-diseases-introduction/
What tools does the Type 2 Inflammation Patient Navigator Provide?
Apart from educational content, the PN also offers a range of other sections::
- Quiz Section: Self-assess your knowledge of your Eosinophilic Driven Diseases (Type 2 inflammation).
- My Experience: You will have the chance to share your experience on a number of yes & no questions, which should give you a better understanding of the topics we discuss on this website. When you are done answering all questions, you will be able to download a PDF of all your answers and share it with your physician.
- Patient Organization Virtual Booth: Check what the participant patient organizations have to offer you, in your own language, and how can you engage with them to get help or get involved with a local patient community in your region of the world.
Who is behind this platform:
This patient navigator is an initiative from GAAPP, with the generous support of AstraZeneca, Sanofi, and Regeneron.